Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02491957 · ClinicalTrials.gov registry record · NA

Impact of LOFT Therapy™ on Breast Cancer Survivors

A NA study, sponsored by Kathy Miller.

Completed
Registry status
NA
Development phase
15
Enrollment target

NCT02491957 is a NA study that has completed, run by Kathy Miller. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02491957, a NA study, has completed, sponsored by Kathy Miller.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and feasibility of LOFT Therapy in breast cancer survivors. In a previous study, the investigators found that many patients are more debilitated at diagnosis than previously recognized. Both chemotherapy and anti-estrogen therapy have a large effect. Within 6 months patients replace muscle with fat leading to a significant reduction in muscle power and endurance. Our data suggests that common exercise recommendations for at least 150 minutes of exercise a week would be far beyond many of our patients' physical ability after therapy, leading to the soreness, injury, frustration, and early discontinuation (or failure to initiate an exercise program in the first place). The degree of muscle loss seen in our patients is similar to that documented in US astronauts after long-term space flight. Our collaborator Dr. Yvonne Cagle, retired USAF flight surgeon, noted that the cosmonauts were in better shape (had less muscle atrophy) than the astronauts. This difference was more than could be explained by the rigorous Russian exercise program. The only key distinction was the compressive, "penguin suits" used by the Russians. This observation lead Dr. Cagle to develop a technique called low intensity, off loaded-compressive therapy (LOFT) to replicate the impact of the Russian penguin suits for patients who were debilitated, whether by space flight or by chronic conditions such as arthritis, Parkinson's disease, and multiple sclerosis. The LOFT method does not require excessive exertion or strain on the joints. In field observations, LOFT therapy improved muscle strength, muscle mass, endurance, sleep quality, and fatigue. This pilot study is the first to evaluate the safety, feasibility, and biologic impact of LOFT on breast cancer survivors.

Interventions

  • OTHER LOFT Therapy

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2015-07-28
Est. Completion 2018-03-29
Phase NA

Sponsor

Kathy Miller

8 total trials

What the Registry Record Tells You About NCT02491957

The ClinicalTrials.gov registry entry for NCT02491957 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathy Miller, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which LOFT Therapy is the first listed.

NCT02491957 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02491957 about?

NCT02491957 is a clinical study titled "Impact of LOFT Therapy™ on Breast Cancer Survivors". The purpose of this study is to evaluate the safety and feasibility of LOFT Therapy in breast cancer survivors. In a previous study, the investigators found that many patients are more debilitated at diagnosis than previously recognized. Both chemotherapy and anti-estrogen therapy have a large effec...

What is the current status of trial NCT02491957?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2015-07-28. Estimated completion is 2018-03-29.

What interventions are being tested in trial NCT02491957?

The interventions under investigation include: LOFT Therapy (OTHER).

Who is sponsoring clinical trial NCT02491957?

This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.